Effect of nicotinic acid/Laropiprant in the Lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype

Cenarro, A. ; Puzo, J. (Universidad de Zaragoza) ; Ferrando, J. ; Mateo-Gallego, R. ; Bea, A. M. ; Calmarza, P. ; Jarauta, E. (Universidad de Zaragoza) ; Civeira, F. (Universidad de Zaragoza)

Resumen: Background: Lipoprotein(a) [Lp(a)] is a lipoprotein in which apolipoproteinB-100 is linked to apolipoprotein(a) [apo(a)]. Significant variation in Lp(a) concentration is specific to LPA gene, which codes for apo(a). Nicotinic acid (NA) is used for treatment of dyslipidemias, and the lowering effect of NA on Lp(a) has been previously reported.
Objective: To evaluate the Lp(a) lowering effect of 1 g/20 mg and 2 g/40 mg day of Nicotinic acid/Laropiprant in subjects with different baseline Lp(a) concentrations and depending on the LPA genotype.
Methods: In an open-label, 10-week study, 1 g/20 mg day of NA/Laropiprant for 4 weeks followed by 6 weeks of 2 g/40 mg day conducted at 3 centers in Spain, 82 subjects were enrolled. Patients were studied at baseline and at the end of both treatment periods and were enrolled in three groups: normal Lp(a) (< 50 mg/dL), high Lp(a) (50–120 mg/dL) and very high Lp(a) (> 120 mg/dL). The LPA genetic polymorphism was analyzed by a real-time PCR.
Results: There was a significant difference in LPA genotypes among Lp(a) concentration groups and an inverse and significant correlation between baseline Lp(a) concentration and LPA genotype was found (R = − 0.372, p < 0.001). There were a significant decrease in total cholesterol, triglycerides, LDL cholesterol, apo B and Lp(a), and a significant increase in HDL cholesterol after NA/Laropiprant treatment, without changes in BMI. However, there were no statistical differences in percentage variation of analyzed variables depending on LPA genotype.
Conclusion: LPA genotype is a major determinant of Lp(a) baseline concentration. However, the lipid lowering effect of NA is not related to LPA genotype.

Idioma: Inglés

DOI: 10.1016/j.metabol.2013.10.014

Año: 2014

Publicado en: METABOLISM-CLINICAL AND EXPERIMENTAL 63, 3 (2014), 365-371
ISSN: 0026-0495

Factor impacto JCR: 3.894 (2014)

Categ. JCR: ENDOCRINOLOGY & METABOLISM rank: 39 / 128 = 0.305 (2014) - Q2 - T1

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)